Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Gasche.
Anemia in IBD: the overlooked villain.
Inflam Bowel Dis, 6 (2000), pp. 142-150
[2.]
F.P. Vleggaar, H.R. Van Buuren, F.H.J. Wolfhagen, S.W. Schalm, H.A.P. Pols.
Prevention and treatment of osteoporosis in primary biliary cirrhosis.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 617-621
[3.]
J.E. Aubin, E. Bonnelye.
Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Osteoporos Int, 11 (2000), pp. 905-913
[4.]
Y.Y. Kong, W.J. Boyle, J.M. Penninger.
Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation, and lymphocyte development.
Immunol Cell Biol, 77 (1999), pp. 188-193
[5.]
Y.Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, et al.
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
Nature, 402 (1999), pp. 304-309
[6.]
J.O. Gordeladze, C.A. Drevon, U. Syversen, J.E. Reseland.
Leptin estimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signalling.
J Cell Biochem, 85 (2002), pp. 825-836
[7.]
W.R. Holloway, F.M. Collier, C.J. Aitken, D.E. Myers, J.M. Hodge, M. Malakellis, et al.
Leptin inhibits osteoclast generation.
J Bone Miner Res, 17 (2002), pp. 200-209
[8.]
J. Kanis, L. Melton, C. Christiansen, C.C.J. Joston, N. Khaltaev.
The diagnosis of osteoporosis.
J Bone Miner Res, 9 (1994), pp. 113-141
[9.]
E.J. Lamb, T. Wong, D.J. Smith, D.E. Simpson, A.J. Coakley, C. Moniz, A.F. Muller.
Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease.
Aliment Pharmacol Ther, 16 (2002), pp. 1895-1902
[10.]
N. Bregenzer, P. Erban, H. Albrich, G. Schmitz, S. Feuerbach, J. Schölmerich, et al.
Screening for osteoporosis in patients with inflammatory bowel disease by using urinary N-telopeptides.
Eur J Gastroenterol, 14 (2002), pp. 599-605
[11.]
R.D. Pollak, F. Karmely, R. Eliakim, Z. Ackerman, D. Rachmilewitz.
Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
Am J Gastoenterol, 95 (2000), pp. 699-704
[12.]
J.A. Silvennoinen, L. Risteli, T.J. Kartunnen, J. Risteli.
Increased degradation of type 1 collagen in patients with inflammatory bowel disease.
Gut, 38 (1997), pp. 223-228
[13.]
L.J. Melton, S. Khosla, E.J. Atkinson, W.M. O'Fallon, B.L. Riggs.
Relationship of bone turnover to bone density and fractures.
J Bone Miner Res, 12 (1997), pp. 1083-1091
[14.]
J.A. Silvennoinen, T.J. Kartunnen, S.E. Niemela, J.J. Manalius, J.K. Lehtola.
A controlled study of bone mineral density in patients with inflammatory bowel disease.
Gut, 37 (1995), pp. 71-76
[15.]
I. Bjarnason, A. Macpherson, C. Mackintosh, M. Buxton-Thomas, I. Forgacs, C. Moniz.
Reduced bone density in patients with inflammatory bowel disease.
Gut, 40 (1997), pp. 228-233
[16.]
S. Gosh, S. Cowen, W.J. Hannan, A. Ferguson.
Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis.
Gastroenterology, 107 (1994), pp. 1031-1039
[17.]
E.J. Schoon, B.M. Blok, B.J. Geerling, M.G. Russel, R.W. Stockbrügger, R.J. Brummer.
Bone mineral density in patients with recently diagnosed inflammatory bowel disease.
Gastroenterology, 119 (2000), pp. 1203-1208
[18.]
C.N. Bernstein, L.L. Seeger, J.W. Sayre, P.A. Anton, L. Artinian, F. Shanahan.
Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.
J Bone Miner Res, 10 (1995), pp. 250-256
[19.]
J. Jahnsen, J.A. Falch, E. Aadland, P. Mowinckel.
Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.
Gut, 40 (1997), pp. 313-319
[20.]
D. Herzog, N. Bishop, F. Glorieux, E.G. Seitman.
Interpretation of bone mineral density values in pediatric Crohn's disease.
Infl Bowel Dis, 4 (1998), pp. 261-267
[21.]
R. Gokhales, M.J. Favus, T. Karrison, M.M. Sutton, B. Rich, B.S. Kirschner.
Bone mineral density assessment in children with inflammatory bowel disease.
Gastroenterology, 114 (1998), pp. 902-911
[22.]
A.M. Boot, J. Bouquet, E.P. Krenning.
de Munick Keizer-Schrama SMPF. Bone mineral density and nutritional status in children with chronic inflamatory bowel disease.
Gut, 42 (1998), pp. 188-194
[23.]
R.J. Motley, E.O. Crawley, C. Evans, J. Rhodes.
Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease.
Gut, 29 (1988), pp. 1332-1336
[24.]
C. Roux, V. Abitbol, S. Chaussade, et al.
Bone loss in patients with inflammatory bowel disease: a prospective study.
Osteoporos Int, 5 (1995), pp. 156-160
[25.]
R. Motley, D. Clements, W.D. Evans, et al.
A four-year longitudinal study of bone loss in patients with inflammatory bowel disease.
Bone and Mineral, 23 (1993), pp. 95-104
[26.]
D. Clements, R.J. Motley, W.D. Evans, et al.
Longitudinal study of cortical bone loss in patients with inflammatory bowel disease.
Scand J Gastroenterol, 27 (1992), pp. 1055-1060
[27.]
J.A. Silvennoinen.
Relationship between vitamin Dparathiroid hormone and bone mineral density in inflammatory bowel disease.
J Intern Med, 239 (1996), pp. 131-137
[28.]
S.H. Scharla, H.W. Minne, U.G. Lempert, et al.
Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis).
Exp Clin Endocrinol, 102 (1994), pp. 44-49
[29.]
R.H.J. Driscoll, S.C. Meredith, M. Sitrin, I.H. Rosenberg.
Vitamin D deficiency and bone disease in patients with Crohn's disease.
Gastroenterology, 83 (1982), pp. 1252-1258
[30.]
J.E. Compston, B. Creamer.
Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection.
Gut, 18 (1997), pp. 171-175
[31.]
I. Hessov, L. Mosekilde, F. Melsen, et al.
Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease.
Scand J Gastoenterol, 19 (1984), pp. 691-696
[32.]
J. Jahnsen, J.A. Falch, P. Mowinckel, E. Aadland.
Vitamin D status, parathiroid hormone and bone mineral density in patients with inflammatory bowel disease.
Scand J Gastroenterol, 37 (2002), pp. 192-199
[33.]
M. Dinca, W. Fries, G. Luissetto, F. Peccalo, F. Bottega, L. Leone, et al.
Evolution of osteopenia in inflammatory bowel disease.
Am J Gastroenterol, 94 (1999), pp. 1292-1297
[34.]
C.N. Bernstein, J.F. Blanchard, C. Metge, M. Yogendran.
The association between corticosteroid use and development of fractures among IBD patients in a population-based database.
Am J Gastroenterol, 98 (2003), pp. 1797-1801
[35.]
S. Holgado, E. Garcia-Planella, M. Mañosa, M. Valls-Roc, M. Sanmartí, E. Domènech, et al.
Bone mass and inflammatory bowel disease.
Ann Rheum Dis, 62 (2003), pp. 532
[36.]
S.H. Ralston.
Genetic control of susceptibility to osteoporosis.
J Clin Endocrinol Metab, 87 (2002), pp. 2460-2466
[37.]
C.M.S. Schulte, A.U. Dignass, H. Goebell, H.D. Röher, K.M. Schulte.
Genetic factors determine extent of bone loss in inflammatory bowel disease.
Gastroenterology, 119 (2000), pp. 909-920
[38.]
C.M. Schulte, H. Goebell, H.D. Röher, K.M. Schulte.
Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.
Dig Dis Sci, 46 (2001), pp. 2521-2528
[39.]
S.R. Cummings, D. Bates, D.M. Black.
Clinical use of bone densitometry.
JAMA, 288 (2002), pp. 1889-1897
[40.]
E.M. Scott, I. Gaywood, B.B. Scott.
Guidelines for osteoporosis in celiac disease and inflammatory bowel disease.
Gut, 46 (2000), pp. 1-8
[41.]
AGA Technical Review on Osteoporosis in Gastrointestinal Diseases.
Gastroenterology, 124 (2003), pp. 795-841
[42.]
D. Marshall, O. Johnell, H. Wedel.
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.
BMJ, 312 (1996), pp. 1254-1259
[43.]
N.K. Arden, C. Cooper.
Assessment of the risk of fracture in patients with gastrointestinal disease.
Eur J Gastroenterol Hepatol, 15 (2003), pp. 865-868
[44.]
P. Vestergaard, K. Krogh, L. Rejmark, S. Laurberg, L. Mosekilde.
Fracture risk is increased in Crohn's disease, but not in ulcerative colitis.
Gut, 46 (2000), pp. 176-181
[45.]
C.N. Bernstein, J.F. Blanchard, W. Leslie, A. Wajda, N. Yu.
Incidence of fracture among patients with inflammatory bowel disease. A population-based study.
Ann Int Med, 133 (2000), pp. 795-799
[46.]
E.V. Loftus, C.S. Crowson, W.J. Sandborn, W.J. Tremaine, W.M. O'Fallon, J. Melton III.
Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota.
Gastroenterology, 123 (2002), pp. 468-475
[47.]
R.W. Stockbrügger, E.J. Schoon, S. Bollani, P.R. Mills, E. Israeli, L. Landgraf, et al.
Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease.
Aliment Pharmacol Ther, 16 (2002), pp. 1519-1527
[48.]
D. Ginard, J. Riera, N. Bonet, L. Barranco, J. Reyes, A. Escarda, et al.
Malabsorción de lactosa en la colitis ulcerosa. Estudio de casos y controles.
Gastroenterol Hepatol, 26 (2003), pp. 469-474
[49.]
E. Domènech, M. Rosinach, M. Maurer-Pons, A. Deselaers, E. Garcia-Planella, I. Bernal, et al.
Dairy products in acute inflammatory bowel disease: should they be excluded from the diet.
Gastroenterology, 122 (2002), pp. A498
[50.]
J. Homik, M.E. Suárez-Almazor, B. Shea, A. Cranney, G. Wells, P. Tugwell.
Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane review) En: The Cochrane Library, Issue 1.
[51.]
J. Homik, A. Cranney, B. Shea, P. Tugwell, G. Wells, R. Adachi, et al.
Biphosphonates for steroid-induced osteoporosis (Cochrane review) En: The Cochrane Library, Issue 1.
[52.]
A. Cranney, V. Welch, J.D. Adachi, J. Homik, B. Shea, M.E. Suárez-Almazor, et al.
Calcitonin for preventing and treating corticosteroid-induced osteoporosis (Cochrane review) En: The Cochrane Library, Issue 1.
[53.]
K.V. Haderslev, L. Tjellesen, H.A. Sorensen, M. Staun.
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.
Gastroenterology, 119 (2000), pp. 639-646
[54.]
V. Abitbol, J.Y. Mary, C. Roux, J.C. Soulés, J. Belaiche, L. Dupas, et al.
Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride.
Aliment Pharmacol Ther, 16 (2002), pp. 919-927
[55.]
J. Siffledeen, T. Chalmers-Nixon, R.N. Fedorak, K. Siminoski, H. Steinhart.
Etidronate plus calcium and vitamin D is equivalent to calcium and vitamin D alone in preventing bone mineral density loss in patients with Crohn's disease.
Gastroenterology, 122 (2002), pp. A62
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
